By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioMarin Pharmaceutical Inc. 

105 Digital Drive

Novato  California  94949  U.S.A.
Phone: 415-506-6700 Fax: 415-382-7427



Company News
BioMarin (BMRN) Stock Halted as FDA Bashes Muscle Wasting Drug 11/25/2015 5:58:28 AM
Investors Hold Their Breath as BioMarin (BMRN)'s DMD Drug Gets Grilled by the FDA Today 11/24/2015 6:15:08 AM
NICE Recommends BioMarin (BMRN)’s Vimizim (Elosulfase Alfa) For The Treatment Of Morquio A Syndrome In England 11/23/2015 11:15:06 AM
BioMarin (BMRN) Release: FDA Posts Briefing Documents For Advisory Committee Meeting To Review Kyndrisa (Drisapersen) For The Potential Treatment Of Duchenne Muscular Dystrophy Amendable To Exon 51 Skipping 11/20/2015 10:47:02 AM
BioMarin (BMRN) Stocks Drop After FDA Panel is Critical of DMD Treatment Drisapersen 11/20/2015 8:19:15 AM
Ernst & Young LLP Names BioMarin (BMRN) CEO Jean-Jacques Bienaime EY Entrepreneur Of The Year 2015 National Award Winner in Life Sciences 11/16/2015 10:54:48 AM
BioMarin (BMRN) To Attend Upcoming Investor Conference In November 10/27/2015 7:47:16 AM
BioMarin (BMRN) Announces FDA Advisory Committee To Review Drisapersen For Treatment Of Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping 10/15/2015 11:37:30 AM
BioMarin (BMRN) To Present Research Results On Duchenne Muscular Dystrophy And Pompe Disease Programs At The 20th International Congress Of The World Muscle Society 10/1/2015 7:58:03 AM
BioMarin (BMRN) Reacquires Kuvan from Merck Serono in Deal Worth More than $500 Million 10/1/2015 5:53:56 AM